Skip to main content

Table 1 Clinicopathological characteristics of neuroendocrine carcinomas at the time of diagnosis (n = 43)

From: Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

Median age (years)

66.0

 Menopausal status

  Premenopausal

2 (4.7%)

  Postmenopausal

39 (90.7%)

  Not confirmed

2 (4.7%)

 T class

  T1

29 (67.4%)

  T2

11 (25.6%)

  T3

2 (4.7%)

  T4

1 (2.3%)

 Mean size of primary tumor, mm (95% CI)

25.3 (18.9-31.7)

 N class

  N0

24 (55.8%)

  N1

10 (23.3%)

  N2

5 (11.6%)

  N3

2 (4.7%)

  Missing

2 (4.7%)

 Mean number of lymph node metastases (95% CI)

2.2 (0.4-3.9)

 Primary distant metastases

  No

39 (90.7%)

  Yes

4 (9.3%)

 HER2 expression

  Negative

40 (93.0%)

  Positive

2 (4.7%)

  Missing

1 (2.3%)

 Estrogen receptor expression

  Negative (0%)

1 (2.3%)

  Low (1-9%)

0 (0%)

  Moderate (10-59%)

0 (0%)

  High (>60%)

41 (97.7%)

  Missing

1 (2.3%)

 Progesterone receptor expression

  Negative (0%)

4 (9.3%)

  Low (1-9%)

6 (14.0%)

  Moderate (10-59%)

6 (14.0%)

  High (>60%)

25 (58.1%)

  Missing

2 (4.7%)

 Ki-67 expression

  Negative (<5%)

1 (2.3%)

  Low (5-14%)

14 (32.6%)

  Moderate (15-30%)

15 (34.9%)

  High (>30%)

11 (25.6%)

  Missing

2 (4.7%)

 Multifocal disease

  Yes

15 (35.9%)

  No

28 (65.1%)

 Synaptophysin expression

  Yes

43 (100%)

  No

0 (0%)

 Chromogranin expression

 

  Yes

30 (69.8%)

  No

9 (20.9%)

  Not available

4 (9.3%)